Effects of enoxaparin on histomorphometric parameters of bones in rats

Polish Journal of Pharmacology

Volumn 56, Issue 4, 2004, Pages 451-457

  Folwarczna, Joanna ^a   Janiec, Waldemar ^a   Gawor, Marta ^a   Pytlik, Maria ^a   Kaczmarczyk Sedlak, Ilona ^a   Nowińska, Barbara ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Enoxaparin; Osteopenia; Rat

Indexed keywords

CALCIUM; ENOXAPARIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MASS; BONE MINERAL; CONTROLLED STUDY; CORTICAL BONE; DIAPHYSIS; DRUG DOSE REGIMEN; DRUG MECHANISM; EPIPHYSIS; FEMALE; FEMUR; METAPHYSIS; MORPHOMETRICS; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPENIA; RAT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TIBIA; VERTEBRA;

ANIMALS; ANTICOAGULANTS; BONE AND BONES; CALCIFICATION, PHYSIOLOGIC; DOSE-RESPONSE RELATIONSHIP, DRUG; ENOXAPARIN; FEMALE; FEMUR; RATS; RATS, WISTAR; SPINE; TIBIA;

EID: 9144231084     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Backos M, Rai R, Thomas E, Murphy M, Doré C, Regan L: Bone density changes in pregnant women treated with heparin: a prospective, longitudinal study. Hum Reprod, 1999, 14, 2876-2880.
2. Bergqvist D: Low molecular weight heparins. J Intern Med, 1996, 240, 63-72.
3. Bhandari M, Hirsh J, Weitz JI, Young E, Venner TJ, Shaughnessy SG: The effects of standard and low molecular weight heparin on bone nodule formation in vitro. Thromb Haemost, 1998, 80, 413-417.
4. Casele HL, Laifer SA: Prospective evaluation of bone density in pregnant women receiving the low molecular weight heparin enoxaparin sodium. J Matern-Fetal Med, 2000, 9, 122-125.
5. Dahlman TC, Sjöberg HE, Ringertz H: Bone mineral density during long-term prophylaxis with heparin in pregnancy. Am J Obstet Gynecol, 1994, 170, 1315-1320.
6. Eikelboom JW, Hankey GJ: Low molecular weight heparins and heparinoids. Med J Austr, 2002, 177, 379-383.
7. Ellison J, Walker ID, Greer IA: Antenatal use of enoxaparin for prevention and treatment of thromboembolism in pregnancy. BJOG, 2000, 107, 1116-1121.
8. Ensom MH, Stephenson MD: Low-molecular-weight heparins in pregnancy. Pharmacotherapy, 1999, 19, 1013-1025.
9. Folwarczna J: Effects of heparin on the skeletal system - review of the literature (Polish) Postepy Osteoartr, 1999, 11, 5-17.
10. Folwarczna J, Janiec W, Barej M, Cegieła. U, Pytlik M, Kaczmarczyk-Sedlak I: Effects of nadroparin on bone histomorphometric parameters in rats. Pol J Pharmacol, 2004, 56, 337-343.
11. Folwarczna J, Pytlik M, Janiec W: Effects of doxycycline on development of changes in histomorphometric parameters of bones induced by bilateral ovariectomy in rats. Pol J Pharmacol, 2003, 55, 433-441.
12. Ginsberg JS, Kowalchuk G, Hirsh J, Brill-Edwards P, Burrows R, Coates G, Webber C: Heparin effect on bone density. Thromb Haemost, 1990, 64, 286-289.
13. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R. Granger C et al.: Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest, 2001, 119, Suppl. 1, 64S-94S.
14. Jones G, Sambrook PN: Drug-induced disorders of bone metabolism. Incidence, management and avoidance. Drug Saf, 1994, 10, 480-489.
15. Kock HJ, Handschin AE: Osteoblast growth inhibition by unfractionated heparin and by low molecular weight heparins: an in vitro investigation. Clin Appl Thromb Hemost, 2002, 8, 251-255.
16. Laurent P, Dussarat GV, Bonal J, Jego C, Talard P, Bouchiat C, Cellarier G: Low molecular weight heparins: a guide to their optimum use in pregnancy. Drugs, 2002, 62, 463-477.
17. Martineau P, Tawil N: Low-molecular-weight heparins in the treatment of deep-vein thrombosis. Ann Pharmacother, 1998, 32, 588-598, 601.
18. Mätzsch T, Bergqvist D, Hedner U, Nilsson B, Østergaard P: Heparin-induced osteoporosis in rats. Thromb Haemost, 1986, 56, 293-294.
19. Mätzsch T, Bergqvist D, Hedner U, Nilsson B, Østergaard P: Effects of low molecular weight heparin and unfragmented heparin on induction of osteoporosis in rats. Thromb Haemost, 1990, 63, 505-509.
20. Muir JM, Andrew M, Hirsh J, Weitz JI, Young E, Deschamps P, Shaughnessy SG: Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo. Blood, 1996, 88, 1314-1320.
21. Muir JM, Hirsh J, Weitz JI, Andrew M, Young E, Shaughnessy SG: A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats. Blood, 1997, 89, 3236-3242.
22. Murray WJ, Lindo VS, Kakkar VV, Melissari E: Long-term administration of heparin and heparin fractions and osteoporosis in experimental animals. Blood Coagul Fibrinolysis, 1995, 6, 113-118.
23. Mutoh S, Takeshita N, Yoshino T, Yamaguchi I: Characterization of heparin-induced osteopenia in rats. Endocrinology, 1993, 133, 2743-2748.
24. Nelson-Piercy C, Letsky EA, de Swiet M: Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk. Am J Obstet Gynecol, 1997, 176, 1062-1068.
25. Nishiyama M, Itoh F, Ujiie A: Low-molecular-weight heparin (dalteparin) demonstrated a weaker effect on rat bone metabolism compared with heparin. Jpn J Pharmacol, 1997, 74, 59-68.
26. Norman D, Miller Y, Sabo E, Misselevich I, Peskin B, Zinman C, Levin D et al.: The effects of enoxaparin on the reparative processes in experimental osteonecrosis of the femoral head of the rat. APMIS, 2002, 110, 221-228.
27. Shaughnessy SG, Hirsh J, Bhandari M, Muir JM, Young E, Weitz JI: A histomorphometric evaluation of heparin-induced bone loss after discontinuation of heparin treatment in rats. Blood, 1999, 93, 1231-1236.
28. Shaughnessy SG, Young E, Deschamps P, Hirsh J: The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria. Blood, 1995, 86, 1368-1373.
29. Tripp EJ, MacKay EH: Silver staining of bone prior to decalcification for quantitative determination of osteoid in sections. Stain Technol, 1972, 47, 129-131.
30. Walenga JM, Bick RL: Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other side effects of heparin therapy. Med Clin North Am, 1998, 82, 635-658.
31. Walton KJ, Duncan JM, Deschamps P, Shaughnessy SG: Heparin acts synergistically with interleukin-11 to induce STAT3 activation and in vitro osteoclast formation. Blood, 2002, 100, 2530-2536.
32. Wolinsky-Friedland M: Drug-induced metabolic bone disease. Endocrinol Metab Clin North Am, 1995, 24, 395-420.